172 related articles for article (PubMed ID: 15358376)
21. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
22. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitination of p53 at multiple sites in the DNA-binding domain.
Chan WM; Mak MC; Fung TK; Lau A; Siu WY; Poon RY
Mol Cancer Res; 2006 Jan; 4(1):15-25. PubMed ID: 16446403
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability.
Dolezelova P; Cetkovska K; Vousden KH; Uldrijan S
FEBS Lett; 2012 Jul; 586(16):2225-31. PubMed ID: 22659184
[TBL] [Abstract][Full Text] [Related]
25. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
26. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
Schon O; Friedler A; Freund S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel mdm2 binding peptides by phage display.
Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
[TBL] [Abstract][Full Text] [Related]
28. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
29. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
[TBL] [Abstract][Full Text] [Related]
30. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
31. NMR structure of a complex between MDM2 and a small molecule inhibitor.
Fry DC; Emerson SD; Palme S; Vu BT; Liu CM; Podlaski F
J Biomol NMR; 2004 Oct; 30(2):163-73. PubMed ID: 15557803
[TBL] [Abstract][Full Text] [Related]
32. MDM2, an introduction.
Iwakuma T; Lozano G
Mol Cancer Res; 2003 Dec; 1(14):993-1000. PubMed ID: 14707282
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
34. Repression of p53-mediated transcription by MDM2: a dual mechanism.
Thut CJ; Goodrich JA; Tjian R
Genes Dev; 1997 Aug; 11(15):1974-86. PubMed ID: 9271120
[TBL] [Abstract][Full Text] [Related]
35. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
36. Structural details on mdm2-p53 interaction.
Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
[TBL] [Abstract][Full Text] [Related]
37. Mdm2: keeping p53 under control.
Piette J; Neel H; Maréchal V
Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
39. Identifying long-range structure in the intrinsically unstructured transactivation domain of p53.
Vise P; Baral B; Stancik A; Lowry DF; Daughdrill GW
Proteins; 2007 May; 67(3):526-30. PubMed ID: 17335006
[TBL] [Abstract][Full Text] [Related]
40. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
Nakamura S; Roth JA; Mukhopadhyay T
Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]